Meet the BD&L Team 2019
Hear from our team and find out more about our approach to partnering.
Search
Our Health and Safety initiative - BE SAFE
Health and safety are of great importance to Boehringer Ingelheim.
Contact Us
Contact our partnering team to discuss your project and learn more about how we can work together.
Partnership canine oncology
The collaboration will focus on identifying new molecules to target cancers in dogs. Small molecules could provide superior disease control.
Expectations towards our business partners
We utilize an extensive network of international suppliers for procuring raw materials, intermediates, packaging materials, technical components and services to deliver our innovative medications worldwide.
Partnership African animal trypanosomiasis
New partnership working on solutions to combat African animal trypanosomiasis
Improving lives by providing better access to treatments
Our ‘Access to Healthcare’ initiative aims to extend support to underserved communities affected by Non-Communicable Diseases
Oncology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
Our evolved employer value proposition
Find out from a father-daughter duo how we live up to our people promise and how our company identifies itself and differentiates from other employers.
Partnering in Central Nervous System Diseases
We are looking for new early-science collaborations. Join our expanding community of innovation partners in central nervous system diseases.
Technologies
We are expanding our global network of technology partners Learn more about partnering with us.
Our Vision
At Boehringer Ingelheim, we have expanded our global research and development activities to tackle eye diseases, specifically those affecting the back of the eye.
Cardiometabolic Diseases
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in CardioMetabolic diseases.
Partnering in Retinal Health
Our partnering interests in retinal diseases offer opportunities for collaboration to complement our pipeline and advance treatment and delivery.
Our goal of transforming DLL3-positive carcinomas
Our progress in developing a potential targeted immunotherapy for DLL3-positive small cell lung cancer and neuroendocrine carcinomas.
Respiratory Diseases
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in respiratory diseases.
Immunology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in immunology.
The power of our people
Diversity & Inclusion is an integral part of Boehringer Ingelheim's identity.
Our Innovation Strategy
A deep understanding of disease, identifying relevant mechanisms and choosing therapeutic modalities to address them is the core of our innovation strategy
Sharing knowledge from our medical device development
Why do we share some of our work beyond Boehringer for free?
Digital Transformation Within Our Global IT
Technology is at the heart of our strategy.
Animal Health: Our Responsibility
Our Responsibility
COVID-19 Protecting Our Employees
Boehringer Ingelheim has taken precautions to protect the health of employees and mitigate the risk of COVID-19 affecting our organization.
Pride Month and our culture of respect
Watch our colleagues from the LGBTQIA+ community and allies share their views.
Announcement for Imagine - our new sustainability story hub
Discover Imagine, our sustainability story hub, showcasing how we drive health equity and advance sustainable healthcare solutions for a better future